Medical News

TAF-IR Study Demonstrates No Effect on IR with TAF-Based Therapies in Healthy Volunteers

Recently a randomized, open-label study was conducted in healthy volunteers, to understand the effect of the tenofovir alafenamide (TAF)-based...

17 Oct, 2018

 
Email this page
Risk of Birth Defects in Babies Born to Mothers Taking Dolutegravir HIV Medicines – EMA Issues Precautionary Advice

The European Medicines Agency (EMA) has issued a precautionary advice on HIV medicine Dolutegravir following the preliminary results of a study...

16 Oct, 2018

 
Email this page
Ultrasensitive Resistance Testing Improves Detection of Virological Failure Risk on First-line ART

A recent case-control study assessing different detection thresholds for pretreatment drug resistance to predict an increased risk of virological...

16 Oct, 2018

 
Email this page
POISE Study: ART Use Reduces Adverse Pregnancy Outcomes in HIV Patients

A recent observational study comparing the pregnancy outcomes among HIV-infected women receiving antiretroviral treatment (ART) and CD4 >350...

05 Oct, 2018

 
Email this page

Key Trials

REALITY: Enhanced Antimicrobial Prophylaxis + ART Improves Survival in Advanced HIV Patients

This study compared the enhanced and standard antimicrobial prophylaxis treatment in patients with advanced HIV disease.

Pre-exposure Chemoprophylaxis with Oral FTC–TDF Prevents HIV Acquisition in Men Who have Sex with Men

Pre-exposure Prophylaxis Initiative (iPrEx) trial was a randomized, double-blind, placebo controlled trial aimed to evaluate the safety and efficacy...

Partners PrEP Study: Oral TDF or TDF–FTC Significantly Reduces the Risk of HIV-1 Acquisition among Heterosexual Men and Women in Serodiscordant Relationships

The Partners PrEP Study is a double-blind, placebo-controlled, phase III clinical trial aimed to assess the safety and efficacy of oral PrEP for the...

Single-Tablet Regimen Containing RPV/FTC/TDF in Virologically Suppressed HIV-1 Patients Improves Cholesterol and Triglycerides

Ritonavir -sparing regimens are recommended in patients  intolerant to ritonavir, to minimise the long-term side effects and  to improve lipid...

Our Publications

Antiretroviral-based Prevention Strategies in HIV

Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...

Antiretroviral Therapy – Current Recommendations

Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....

Datasheet: Lopinavir and Ritonavir (40mg/10mg) Oral Pellets

Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...

Fast Facts: Lopinavir and Ritonavir (40 mg/10 mg) Oral Pellets

Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...

Patient Education

Live Healthier, Live Longer

This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment...

Living with Hope

This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects...

Slide Library

HIV - HCV Coinfection

This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...

 
Email this page
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use

PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...

 
Email this page
HIV- Post-exposure Prophylaxis (PEP)

Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...

 
Email this page
Isoniazid Preventive Therapy in HIV Infection

HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....

 
Email this page

Poll

Which is your preferred 3rd drug in a first-line regimen?
Efavirenz 600
50% (1 vote)
Efavirenz 400
0% (0 votes)
Dolutegravir
50% (1 vote)
Total votes: 2